论文部分内容阅读
目的评价埃克替尼联合三维适型放疗治疗中晚期非小细胞肺癌(NSCLC)的近期疗效及毒副作用。方法将60例中晚期NSCLC患者分为两组,其中单纯放疗组(30例)采用三维适型放射治疗,使用6MV-X线直线加速器,照射野包括原发病灶、肺门、纵隔和受累锁骨上区,原发灶总照射剂量为66~70Gy,淋巴结引流区总照射剂量为50-60Gy;联合治疗组(30例)在采用三维适型放射治疗的同时加用盐酸埃克替尼150mg,3次/日口服,直至病变进展或其他原因停药。结果60例患者均完成治疗计划,联合治疗组总有效率为83.3%,明显高于单纯放疗组53.6%的总有效率(P<0.01);联合治疗组的1、2年生存率也均高于单纯放疗组(P<0.05);两组不良反应发生率比较无统计学差异(P>0.05)。结论盐酸埃克替尼联合三维适型放疗治疗中晚期NSCLC有较好的近期疗效,可提高生存率。毒性反应可耐受。
Objective To evaluate the short-term curative effect and toxicity of imatinib in combination with three-dimensional conformal radiotherapy for advanced non-small cell lung cancer (NSCLC). Methods Sixty patients with advanced non-small cell lung cancer (NSCLC) were divided into two groups. Radiotherapy (including 6 cases of primary lesion, hilar, mediastinum and affected clavicle) In the upper zone, the total primary radiation dose was 66-70 Gy and the total radiation dose in the lymph node drainage zone was 50-60 Gy. In the combination therapy group (30 cases), three-dimensional conformal radiation therapy was used together with 150 mg of imatinib hydrochloride, 3 times / day orally, until the progress of the disease or other reasons withdrawal. Results All 60 patients completed the treatment plan. The total effective rate was 83.3% in the combination therapy group, which was significantly higher than the 53.6% (P <0.01) in the radiotherapy alone group. The 1- and 2-year survival rates were also higher in the combined therapy group In the radiotherapy alone group (P <0.05), the incidence of adverse reactions was no significant difference between the two groups (P> 0.05). Conclusion The combination of imatinib hydrochloride and three-dimensional stereotactic radiotherapy in the treatment of advanced NSCLC has good short-term curative effect and can improve the survival rate. Toxicity is tolerable.